Pivekimab sunirine CD123 BPDCN blastic plasmacytoid neoplasm

Indicated For

Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

About This Medication

# Pivekimab Sunirine Patient Guide: How to Get Pivekimab Sunirine at Low or No Cost Pivekimab sunirine (PVEK) is an investigational antibody-drug conjugate (ADC) targeting CD123 for treating aggressive blood cancers like relapsed/refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).[2][3][4][5][7] As of March 2026, it is not yet FDA-approved, so no established patient assistance program exists from its developer AbbVie; patients should monitor for approval and check AbbVie or general resources like Pfizer RxPathways for similar therapies while in clinical trials.[5][7][8] ## About Pivekimab Sunirine **Pivekimab sunirine** is a next-generation ADC designed to deliver chemotherapy directly to cancer cells expressing CD123, a protein common in AML and BPDCN, minimizing damage to healthy cells.[3][4][5] Clinical data show promising results: - In relapsed/refractory AML monotherapy, it achieved a 21% overall response rate (ORR).[3] - Combined with azacitidine and venetoclax in newly diagnosed AML, 54% complete response (CR) and 76% minimal residual disease (MRD) negativity.[3] - In frontline BPDCN (CADENZA trial), 75% CR/CRc and 80% ORR.[7] Side effects may include febrile neutropenia, infusion reactions, and anemia.[3] It's administered via IV infusion, often in cycles (e.g., day 7 of 28-day cycles).[3][9] AbbVie submitted a BLA to the FDA in September 2025 for BPDCN; approval could enable access programs.[5][7] Discuss with your oncologist if you're eligible for ongoing trials (e.g., NCT06034470).[9] ## Who Qualifies for Assistance? No specific program exists yet for **pivekimab sunirine**, as it's investigational.[2][5] Once approved, expect programs similar to AbbVie or Pfizer Oncology models:[1][6][8] - **Uninsured or low-income**: Free medicine if income ≤400-500% FPL (federal poverty level), no government insurance.[6] - **Commercially insured**: Co-pay cards reducing costs to $0, up to $10,000-$25,000/year, excluding Medicare/Medicaid.[1][6] Contact AbbVie Patient Assistance (1-800-222-6885) or check abbvie.com/patients for updates.[8] ## Income Eligibility Breakdown Hypothetical table based on standard pharma programs (e.g., Pfizer RxPathways); confirm with AbbVie post-approval. Assumes 400% FPL threshold for free drug.[2][6] | Household Size | Annual Income Limit (2026 est.) | Notes | |----------------|--------------------------------|-------| | 1 (Individual) | $60,320 | ≤400% FPL[6] | | 2 (Couple) | $81,760 | Common threshold[2] | | 3 | $103,280 | Varies by program | | 4 | $124,800 | Add ~$21,520 per person | **Notes**: FPL adjusts yearly; government insurance often disqualifies free programs but may allow co-pay help.[1][6] Pfizer examples exclude Medicare/Medicaid.[1] ## Insurance Requirements - **Commercial insurance**: Likely eligible for co-pay assistance ($0 out-of-pocket, annual caps $4,000-$25,000).[1][6] - **Government insurance (Medicare, Medicaid, VA, TRICARE)**: Ineligible for co-pay cards; may qualify for free drug if low-income.[6] - **Uninsured**: Prime candidates for free medication via patient assistance foundations.[2][6] If enrolled in Medicare Extra Help, pair with programs like Pfizer's.[6] ## Step-by-Step Application Process 1. **Verify eligibility**: Use prescriber portal or call AbbVie (est. 1-800-222-6885) to check income/insurance.[8] 2. **Gather documents**: Proof of income (tax returns, pay stubs), insurance card, prescription, ID.[1] 3. **Get prescription**: Oncologist submits via e-application or fax.[2] 4. **Apply online/phone**: Visit abbvie.com/patients or pfizerRxpathways.com for models; download forms.[2][8] 5. **Submit**: Mail/fax with docs; track status online.[1] 6. **Approval**: Expect 1-2 weeks; medication ships to doctor/pharmacy.[6] For trials, ask your doctor about compassionate use or expanded access. ## Timeline and Delivery - **Processing**: 5-14 business days typically.[1] - **Delivery**: Free to prescriber's office or home; specialty pharmacy for infusions.[6] - **Refills**: Auto-ship or reapply every 12 months; reauthorization needed.[1] ## Alternatives if Denied or Ineligible - **Pfizer RxPathways**: Free Pfizer oncology meds for uninsured/low-income (351,000 prescriptions in 2024).[2] - **General resources**: NeedyMeds.org, RxAssist.org, PAN Foundation. - **Co-pay foundations**: CancerCare, LLS co-pay programs. - **Trials**: Search clinicaltrials.gov for pivekimab sunirine (e.g., NCT06034470).[9] - **Biosimilars**: None available; monitor for generics post-approval.[] ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Pivekimab sunirine is investigational; no program confirmed.[3][5] Eligibility/terms change; contact manufacturer directly. Consult your healthcare provider. Income tables estimated from similar programs.[1][2][6] (Word count: 912)

Program information last verified: March 30, 2026